Pharmacology is the biomedical science concerned with the study of drugs: their sources, chemical properties, mechanisms of action, effects on living systems, therapeutic applications, and toxicity. The discipline spans the full continuum from molecular interactions at receptor binding sites to population-level patterns of drug response, and it underpins rational prescribing across every clinical specialty. Understanding pharmacology begins with appreciating how its major subdivisions relate to one another and to clinical practice.
The two foundational subdivisions of pharmacology are pharmacokinetics and pharmacodynamics. Pharmacokinetics (PK) describes what the body does to a drug: the processes of absorption, distribution, metabolism, and excretion (ADME) that collectively determine how much drug reaches its site of action, when it arrives, and how long it remains. Pharmacodynamics (PD) describes what the drug does to the body: the biochemical and physiological effects produced when a drug interacts with its molecular target, and the relationship between drug concentration and the magnitude of those effects. In practice, PK and PD are inseparable: an inadequate pharmacokinetic profile means that even a drug with potent pharmacodynamic properties will fail to produce a useful clinical effect, while a drug with favorable pharmacokinetics but weak receptor affinity will similarly disappoint. The integrated PK/PD (pharmacokinetic/pharmacodynamic) relationship determines the dose-response curve that guides clinical dosing decisions.1
Pharmacogenomics. Pharmacogenomics examines how inherited genetic variation influences an individual's response to drugs, encompassing both pharmacokinetic variability (e.g., differences in drug-metabolizing enzyme activity caused by single nucleotide polymorphisms (SNPs)) and pharmacodynamic variability (e.g., differences in receptor structure or signaling pathway components that alter drug efficacy or toxicity). The term pharmacogenomics is often used interchangeably with pharmacogenetics, though the former refers more broadly to genome-wide approaches while the latter historically referred to single-gene variants. Clinical pharmacogenomics has moved beyond the research setting and now informs prescribing of drugs including warfarin, clopidogrel, codeine, azathioprine, and abacavir, where genotype-guided dosing or drug selection meaningfully reduces adverse outcomes.2
Toxicology. Toxicology is the study of the adverse effects of chemical agents on living systems, including both drugs and environmental or occupational chemical exposures. Clinical toxicology focuses on the diagnosis and management of poisoning and drug overdose, while regulatory toxicology informs the safety evaluation of drugs and chemicals entering the marketplace. The distinction between a drug and a poison is often one of dose and context: many therapeutic agents are acutely toxic at supratherapeutic concentrations, and many toxins have therapeutic applications at carefully controlled doses. The concept of the therapeutic index (TI) -- the ratio of the toxic dose to the effective dose -- formalizes this dose-dependency and is one of the most practically important pharmacological concepts in clinical medicine.1
Clinical Pharmacology. Clinical pharmacology applies pharmacological principles directly to patient care, bridging the gap between laboratory science and bedside practice. It encompasses the conduct and interpretation of clinical pharmacokinetic studies, therapeutic drug monitoring (TDM), evaluation of drug-drug interactions, management of drugs in special populations (renal and hepatic impairment, pregnancy, extremes of age, obesity), and the design of rational dosing regimens. In hospital and academic medical center settings, clinical pharmacologists serve as consultants on complex dosing problems and as contributors to formulary and prescribing policy decisions. The discipline also overlaps substantially with clinical pharmacoepidemiology, which studies drug effects at the population level using real-world data from large patient databases and spontaneous adverse event reporting systems.3
Every clinical question about a drug can be framed as either a PK question (Is enough drug reaching the target site? Is the drug being cleared too rapidly or too slowly?) or a PD question (Is the drug producing the intended molecular effect at the target? Is there a reason the target is not responding?). Separating the two provides a structured approach to drug failure, toxicity, and dose adjustment that applies across all drug classes and clinical settings.
Every drug in clinical use carries at least three distinct names: a chemical name, a generic (nonproprietary) name, and one or more brand (proprietary) names. Understanding the naming system is not merely academic -- it has direct implications for safe prescribing, generic substitution, drug interaction recognition, and communication across international healthcare systems.
Chemical Names. The chemical name of a drug is a systematic descriptor based on the rules of the International Union of Pure and Applied Chemistry (IUPAC) that specifies the precise molecular structure of the compound. Chemical names are unambiguous but are typically unwieldy for clinical use. For example, the chemical name for the analgesic acetaminophen is N-(4-hydroxyphenyl)acetamide. Chemical names are used principally in pharmaceutical chemistry and regulatory submissions rather than in clinical practice or prescribing.4
Generic and Nonproprietary Names. The generic or nonproprietary name of a drug is the standardized, publicly owned name assigned by a recognized naming authority. The most important international framework is the International Nonproprietary Name (INN) system, established by the World Health Organization (WHO) in 1953. The INN programme assigns a single, unique global name to each active pharmaceutical ingredient to ensure unambiguous identification across languages, countries, and healthcare systems. In the United States (US), the parallel naming body is the United States Adopted Name (USAN) Council, a collaborative body of the American Medical Association (AMA), the United States Pharmacopeia (USP), and the American Pharmacists Association (APhA), with FDA participation. USAN and INN names are virtually always identical for modern drugs. INNs are organized into stem groups: drugs sharing a common suffix or prefix (a stem) typically belong to the same pharmacological class, a convention that encodes structural and mechanistic information directly into the drug name. For example, all beta-blockers end in -olol (metoprolol, atenolol, carvedilol), all angiotensin-converting enzyme (ACE) inhibitors in -pril (enalapril, lisinopril, ramipril), and all proton pump inhibitors (PPIs) in -prazole (omeprazole, lansoprazole, pantoprazole).45
Brand Names. A brand name (trade name, proprietary name) is assigned by the pharmaceutical manufacturer and is protected by trademark law. A single generic drug may carry multiple brand names in different countries or from different manufacturers. Once the patent protecting a drug expires, other manufacturers may produce and sell the same active ingredient under its generic name or under new brand names; these products are generics. The US Food and Drug Administration (FDA) approves generic drugs through the Abbreviated New Drug Application (ANDA) process, which requires demonstration of bioequivalence to the reference listed drug rather than independent proof of safety and efficacy. Prescribing by generic name is standard practice in most institutional settings and is encouraged in outpatient practice to reduce cost and minimize brand-substitution errors.5
Drug Sources. Therapeutic agents derive from four principal sources. Natural sources include plants, animals, and microorganisms: classic examples are morphine (derived from the opium poppy Papaver somniferum), digoxin (from Digitalis lanata), and penicillin (from Penicillium molds). Synthetic drugs are manufactured entirely by chemical synthesis without a natural precursor; most modern small-molecule drugs fall into this category. Semisynthetic drugs are produced by chemically modifying a natural compound to improve potency, selectivity, pharmacokinetic properties, or toxicity profile; ampicillin and the semisynthetic opioids oxycodone and hydrocodone are familiar examples. Biologic drugs, increasingly important in modern therapeutics, are large-molecule agents produced by living cell systems using recombinant DNA (deoxyribonucleic acid) technology; they include monoclonal antibodies, therapeutic proteins such as recombinant insulin and erythropoietin, vaccines, gene therapies, and cell-based therapies. The regulatory pathway for biologics differs from that for small-molecule drugs, reflecting the greater complexity of their manufacture and characterization.13
Learning common INN stems allows immediate class identification from a drug name alone, even for unfamiliar agents. Key stems: -olol (beta-blockers), -pril (ACE inhibitors), -sartan (angiotensin II receptor blockers), -statin (HMG-CoA reductase inhibitors), -prazole (proton pump inhibitors), -mab (monoclonal antibodies), -cept (receptor fusion proteins), -nib (small-molecule kinase inhibitors), -cycline (tetracycline antibiotics), -floxacin (fluoroquinolone antibiotics). Recognizing stems reduces the cognitive load of managing large drug formularies and supports rapid adverse effect and interaction recognition.
The path from a candidate molecule to an approved therapeutic is lengthy, expensive, and subject to extensive regulatory oversight designed to ensure that drugs reaching patients are both safe and effective. Understanding this process equips clinicians to interpret clinical trial data, evaluate the strength of evidence behind drug approvals, and appreciate why newly approved drugs may carry significant residual uncertainty about their long-term safety profiles.
Preclinical Development. Before any drug is tested in humans, it must undergo preclinical evaluation encompassing in vitro studies of mechanism and selectivity, pharmacokinetic profiling in animal models, and formal toxicology studies (acute, subacute, and chronic toxicity; genotoxicity; reproductive toxicity; and, where relevant, carcinogenicity). These studies are conducted under Good Laboratory Practice (GLP) guidelines and provide the basis for an Investigational New Drug (IND) application submitted to the FDA, which must be approved before human trials can begin. Preclinical data identify the likely starting dose for first-in-human studies, characterize the expected toxicity profile, and provide mechanistic support for the drug's proposed indication. Despite rigorous preclinical evaluation, the majority of drugs entering clinical development ultimately fail to gain approval: approximately 90% of IND applications do not result in an approved drug, most commonly because of inadequate efficacy or unacceptable toxicity discovered in clinical trials.6
Phase I Clinical Trials. Phase I trials are first-in-human studies conducted in small numbers of participants, typically 20 to 100 healthy volunteers or, for oncology drugs where safety in healthy volunteers is ethically untenable, in patients with the target disease. The primary objectives are to establish safety and tolerability, characterize the pharmacokinetic profile (absorption, distribution, metabolism, excretion), identify dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD). Phase I trials use dose-escalation designs, beginning with a low starting dose derived from preclinical data and increasing in cohorts until a predetermined toxicity threshold is reached. They are not designed to demonstrate efficacy. Completion of Phase I provides the pharmacokinetic and safety data needed to select doses for Phase II studies.67
Phase II and Phase III Trials. Phase II trials expand testing to a larger population of patients with the target condition, typically 100 to 500 participants, with the dual objectives of generating preliminary evidence of efficacy and further characterizing the safety profile at therapeutically relevant doses. Phase II studies are often uncontrolled or use historical controls; they generate the signal of efficacy that justifies the larger investment of Phase III. Phase III trials are pivotal, large-scale randomized controlled trials (RCTs) conducted in hundreds to thousands of patients with the target condition, comparing the investigational drug against placebo or an active comparator using a pre-specified primary endpoint. The FDA generally requires at least two adequate and well-controlled Phase III trials demonstrating substantial evidence of effectiveness before approving a standard New Drug Application (NDA). For biologic drugs, the parallel submission is a Biologics License Application (BLA). The FDA also maintains expedited pathways for drugs addressing serious or life-threatening conditions with unmet medical need, including Fast Track designation, Breakthrough Therapy designation, Accelerated Approval (based on surrogate endpoints), and Priority Review.67
Phase IV and Post-Marketing Surveillance. Phase IV studies are conducted after drug approval and serve multiple purposes: characterizing safety signals in broader and more diverse populations than those enrolled in pivotal trials, identifying rare adverse events too infrequent to detect even in large Phase III programs, evaluating the drug in special populations (pediatric patients, pregnant women, patients with comorbidities) excluded from pre-approval trials, and sometimes expanding the approved indication. Post-marketing surveillance also encompasses spontaneous adverse event reporting systems: in the US, the FDA MedWatch program collects voluntary reports from healthcare providers and mandatory reports from manufacturers. The FDA Adverse Event Reporting System (FAERS) database aggregates these reports and is used to detect pharmacovigilance signals that may trigger label updates, risk mitigation strategies, or, in rare cases, market withdrawal. Many important safety signals -- including the cardiovascular risks of selective COX-2 (cyclooxygenase-2) inhibitors, the association of thiazolidinediones with bladder cancer, and the bone and cardiovascular effects of long-term bisphosphonate use -- emerged from post-marketing surveillance rather than pre-approval trials.78
Standard NDA/BLA: requires two adequate Phase III RCTs; review time approximately 10-12 months. 505(b)(2) NDA: relies partly on data from previously approved drugs; used for new formulations, new indications, or new combinations. ANDA (generic): requires bioequivalence demonstration only; no independent efficacy data required. Accelerated Approval: based on surrogate endpoint reasonably likely to predict clinical benefit; post-marketing confirmatory trials required. Biosimilar: demonstrates no clinically meaningful difference from reference biologic in PK, PD, safety, and efficacy; abbreviated approval pathway under the Biologics Price Competition and Innovation Act.
The route by which a drug is administered is not merely a delivery detail: it is a primary pharmacokinetic determinant that governs the rate and completeness of absorption, the extent of presystemic metabolism, the time to peak plasma concentration, and the practical feasibility of dose adjustment. Selecting an appropriate route is an integral part of rational drug prescribing and must be matched to the clinical context.
Enteral Routes. The oral route is the most convenient, most commonly used, and most studied route of drug administration. Orally administered drugs are absorbed primarily in the small intestine, where the large surface area and rich blood supply favor passive diffusion of lipophilic, un-ionized drug molecules across the enterocyte membrane. Bioavailability via the oral route is reduced by first-pass metabolism: drugs absorbed from the gastrointestinal (GI) tract enter the portal circulation and pass through the liver before reaching the systemic circulation, where hepatic and intestinal enzymes may substantially metabolize the drug before it reaches its target. The sublingual route (drug dissolved under the tongue) allows absorption directly into the systemic venous circulation, bypassing first-pass metabolism entirely; nitroglycerin and buprenorphine are examples of drugs where this route is clinically important. Rectal administration has variable and unpredictable bioavailability but avoids first-pass metabolism for drugs absorbed from the distal rectum; it is a practical option in patients who cannot take oral medications.1
Parenteral Routes. Parenteral routes bypass the gastrointestinal tract entirely. Intravenous (IV) administration delivers drug directly into the systemic circulation, achieving 100% bioavailability by definition, the most rapid onset of action, and the most precise control of plasma concentrations -- advantages that make it the preferred route for urgent clinical situations, for drugs with very poor oral bioavailability, and for drugs requiring precise titration. Intramuscular (IM) administration deposits drug into muscle tissue, from which absorption occurs by diffusion into capillaries; onset is faster than oral but slower than IV, and bioavailability is generally high. Subcutaneous (SC) administration deposits drug into the hypodermis; absorption is slower than IM and may be prolonged for depot formulations. Inhalation delivers drug to the pulmonary epithelium, which provides a large absorptive surface and direct access to the pulmonary circulation with minimal first-pass effect; it is the preferred route for bronchodilators and inhaled corticosteroids (ICS) because it maximizes drug delivery to the airway while minimizing systemic exposure. Transdermal delivery through the skin is useful for drugs with appropriate physicochemical properties (moderate molecular weight, adequate lipophilicity) and provides sustained, zero-order release avoiding first-pass metabolism; fentanyl, nicotine, estradiol, and clonidine are examples.13
Elements of Rational Prescribing. Rational prescribing requires integrating pharmacological knowledge with patient-specific clinical information to select the right drug, at the right dose, by the right route, for the right duration, in the right patient. This framework operationalizes several core principles. First, a clear diagnosis or therapeutic goal must precede drug selection: prescribing without a defined indication exposes patients to drug risk without defined benefit. Second, drug selection should be based on evidence of efficacy and safety for the specific indication, with preference for drugs with established long-term safety records over newer alternatives with limited post-marketing data where therapeutically equivalent. Third, the dose must be individualized based on pharmacokinetic variables including weight, renal and hepatic function, age, and genetic factors, rather than applied as a universal fixed quantity. Fourth, drug interactions must be assessed prospectively using all drugs the patient is taking, including over-the-counter (OTC) medications, herbal supplements, and drugs prescribed by other providers. Fifth, the prescriber must establish a monitoring plan with defined parameters and intervals appropriate to the drug's toxicity profile and the patient's risk factors.38
Pharmacology encompasses PK (body acts on drug: ADME) and PD (drug acts on body: receptor interaction, concentration-effect relationship), plus pharmacogenomics, toxicology, and clinical pharmacology. Drug names exist at three levels: chemical (IUPAC), generic/INN (WHO system, stems encode class), and brand (proprietary, trademark-protected). Drug sources: natural, synthetic, semisynthetic, biologic. Development sequence: preclinical (GLP toxicology) → IND → Phase I (safety/PK) → Phase II (preliminary efficacy) → Phase III (pivotal RCTs) → NDA/BLA → Phase IV (post-marketing surveillance). Route of administration is a primary PK determinant governing bioavailability, onset, and first-pass effect. Rational prescribing: right drug, dose, route, duration, patient -- with individualized monitoring.
Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2019. ISBN 9780702074486.
ISBN 9780702074486Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343-350.
doi:10.1038/nature15817Atkinson AJ Jr, Huang SM, Lertora JJL, Markey SP, eds. Principles of Clinical Pharmacology. 3rd ed. London: Academic Press; 2012. ISBN 9780123854711.
ISBN 9780123854711Serafini M, Cargnin S, Massarotti A, Tron GC, Pirali T, Genazzani AA. What's in a name? Drug nomenclature and medicinal chemistry trends using INN publications. J Med Chem. 2021;64(13):9297-9313.
doi:10.1021/acs.jmedchem.1c00181World Health Organization. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: WHO; 2013. WHO/EMP/RHT/TSN/2013.1.
who.int/medicines/services/inn/StemBook_2013_Final.pdfHay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51.
doi:10.1038/nbt.2786Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. Fundamentals of Clinical Trials. 5th ed. New York: Springer; 2015. ISBN 9783319185385.
doi:10.1007/978-3-319-18539-2Waller DG, Sampson AP. Medical Pharmacology and Therapeutics. 5th ed. Edinburgh: Elsevier; 2018. ISBN 9780702071676.
ISBN 9780702071676